Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May
2024年5月14日 - 9:00PM
Revolo Biotherapeutics (“Revolo” or the “Company”), a company
developing therapies that reset the immune system to achieve
superior remission for patients with autoimmune and allergic
diseases, today announced that it will present at two medical
meetings in May: The American Thoracic Society (ATS) 2024
International Conference and the 6th Treg Directed Therapies
Summit.
ATS 2024 – May 17-22, San
DiegoFormat: Poster
PresentationTitle: IRL201104, A Novel
Immunomodulatory Peptide, Shows Efficacy on Inflammatory Endpoints
and Airway Hyperresponsiveness in a House Dust Mite Driven Model of
Allergic Inflammation with or Without Poly I:C
ExacerbationPoster Number:
804Session: D21 - Terminator: Control of Airway
Inflammation and Immune Response in AsthmaPoster Discussion
Date and Time: Wednesday, May 22, 8:15-10:15 a.m.
PTRoom: San Diego Convention Center, Room 31A-C
(Upper Level)Presenter: Jorge De Alba, Vice
President of Discovery and Translational Science, Revolo
More information about the ATS 2024 can be accessed here.
6th Treg Directed Therapies Summit – May 21-23,
BostonFormat: Oral
PresentationTitle: ‘1104, an immune-resetting
peptide, for the treatment of allergic
diseaseTrack: Non-Cell Based
ApproachesSession: Utilizing Novel Platform
Technology to Amplify Treg Induction In-VivoPresentation
Date and Time: Wednesday, May 22, 12:00-12:30 p.m.
ETPresenter: Roly Foulkes, Chief Scientific
Officer, Revolo
More information about the 6th Treg Directed Therapies Summit
can be accessed here.
Revolo BiotherapeuticsRevolo Biotherapeutics is
developing therapies that reset the immune system to achieve
remission for patients with autoimmune and allergic disease,
without the immune system suppression seen with current therapies.
Its two drug candidates, ‘1805 and ‘1104, reset the immune system
from a pro-inflammatory state to a regulated homeostatic state, by
inducing T regulatory and B regulatory cells after just one dose.
‘1104, a first-in-class peptide, has been evaluated in two Phase 2a
trials: one in patients with eosinophilic esophagitis (EoE) and
another in patients with allergen sensitivity. ‘1104 is now
advancing towards evaluation in a Phase 2b trial in EoE and a Phase
2a trial in atopic dermatitis or asthma, while the company explores
its additional potential for other allergic diseases. ‘1805, a
modified analogue of a key protein in immune function, is planned
to be assessed in a second Phase 2 clinical trial in patients with
moderate-to-severe rheumatoid arthritis and a Phase 2a clinical
trial for ulcerative colitis. The disease-agnostic mechanism of
action of Revolo Biotherapeutic’s assets provides a potential
platform for the development of treatments for multiple autoimmune
and allergic diseases.
For further information, please
visit www.revolobio.com.
Company ContactWoody Bryan, Ph.D.President and
CEOwbryan@revolobio.com
Media ContactMichael RubensteinLifeSci
Communications+1 561-289-7981mrubenstein@lifescicomms.com